what’s new in the biology of cml? john goldman imperial college london newcastle, 1 st march 2013
TRANSCRIPT
Molecular features of BCR-ABL1
BCR-ABL1 as a clinical target
Signal transduction pathways
Signal transduction molecules as clinical targets
Stem cells as clinical targets
Some outstanding biological issues in CML
Molecular features of BCR-ABL1
BCR-ABL1 as a clinical target
Signal transduction pathways
Signal transduction molecules as clinical targets
Stem cells as clinical targets
Some outstanding biological issues in CML
BCR-ABL1 activates a myriad of signaling pathwaysBCR-ABL1 activates a myriad of signaling pathways
Goldman and Melo, NEJM 2003; 349: 1451, modified by van Etten, 2010
Tyr177
STAT1
STAT5P
LYNP
JAK2P
AHI1
BCL6
mTOR
Smo
GLI-1
GSK3
eIF4E
CatP
BCLX
Molecular features of BCR-ABL1
BCR-ABL1 as a clinical target
Signal transduction pathways
Signal transduction molecules as clinical targets
Stem cells as clinical targets
Some outstanding biological issues in CML
BCR-ABL1 activates a myriad of signaling pathwaysBCR-ABL1 activates a myriad of signaling pathways
Goldman and Melo, NEJM 2003; 349: 1451, modified by van Etten, 2010
Tyr177
STAT1
STAT5P
LYNP
JAK2P
AHI1
BCL6
mTOR
Smo
GLI-1
GSK3
eIF4E
CatP
BCLX
Approaches to increasing the efficacy of TKI
Exploitable differences
EpigeneticsHLA class II
Cell cycle regulationChemokinesPML/PTEN
PP2AFoxOBCL6
CytokinesCXCR4
WntHedgehog
Autophagy Alox 5/15
Immune basedGenomic instability
ROS
Actual approaches
HDAC-inh.ArsenicFTY720
TGFinh.RI-BP1
Jak2-inh.Plerixafor
GSK3inh.Smo inhibitors0H-chloroquine
ZileutonImmunotherapy
PARP-inh.
Approaches to increasing the efficacy of TKI
Exploitable differences
EpigeneticsHLA class II
Cell cycle regulationChemokinesPML/PTEN
PP2AFoxOBCL6
CytokinesCXCR4
WntHedgehog
Autophagy Alox 5/15
Immune basedGenomic instability
ROS
Actual approaches
HDAC-inh.&Demeth. agents
ArsenicFTY720
TGFinh.RI-BP1
Jak2-inh.Plerixafor
GSK3inh.Smo inhibitors0H-chloroquine
ZileutonImmunotherapy
PARP-inh.
Cancerous inhibitor of PP2A (CIP2A) predicts progression to BT
Lucas et al, Blood 2011; 117: 6660-6668
PP2A is a tumor suppressor that is inactivated by BCR-ABL1 signaling,
CIP2A also renders protein phosphatase 2A (PP2A) inactive
Patients with high levels of CIP2A progress to BT, whereas patients with lower levels do not, and
CIP2A may act through altered phosphorylation of MYC on S62
SET
JAK2
IM
PP2A
c-MycSer62
BCR-ABL1
CIP2A
Lucas et al, Blood 2011; 117: 6660-6668
Diagnosis Diagnosis Diagnosis
CCyR No CCyR BC
CIP2A at diagnosis as a predictive marker for response to TKI
25
20
15
10
5
0
CIP
2A
(M
FI)
Probability of disease progression stratified by CIP2A level at diagnosis
Patients with a high diagnostic CIP2A protein level have 100% probability of progressing to blast crisis (p=<0.0001).
Normal
A B
Low CIP2AHigh CIP2A
C
C C R e N o C C R e B C
p=<0.001
p=0.007
Diagnosis 12 months
C C R e N o C C R e B C
Diagnosis 12 months Diagnosis 12 months
MNC CD34+ cells
Progression-free survival
P=0.017
Lucas CM et al. Blood 2011
Low
High
Activation of the Sonic hedgehog pathway in chronic myeloid leukemia
The levels of Shh, Smo and Gli are increased in chronic phase and considerably more increased in
advanced phases of CML
Bing Long et al, J Exper Clin Cancer Research 2011; 30:8
Expression of Shh and its receptors in different phases of CML
Shh Patched Smo Gli1
SHH + PTCH1
SMO
GLI1GSK3
Sufu
P
Target Genes(e.g. PTCH1, GLI1, Myc)
sFRP-1
-catenin
Target Genes(e.g. cyclinD1, CD44)
Wnt + Frizzled?
-catenin + TCFGLI1+GLI3
Proposed cross-talk between Shh and WNT pathways in CML
Sabutoclax, a pan BCL2 inhibitor renders bone marrow resident leukemia stem cell
sensitive to TKI
Goff et al, Cell Stem Cell, 2013; 12: 1-13
Peptide inhibition of BCL6 with retroinverso BCL6 peptide inhibitor (RI-BPI) compromises colony formation in CML and selectively eradicates CD34+ CD38- leukemia initiating cells
Hurtz et al. J Exper Med 2011; 208: 2016
BCL6-mediated repression of p53 is critical for CML LSC survival
BCL6-mediated repression of p53 is critical for CML LSC survival
Hurtz et al, J Exper Med 2011;11: 2163-2174
Inhibitory effect of a retro-inverso BCL6 peptide Inhibitor (RI-BPI)
ADAR1 promotes myeloid progenitor re-programming in CML
Jiang et al, PNAS 2013; 110: 1041
Isoform diversity can be generated by RNA editing by adenosine deaminase activation of RNA (ADAR) enzymes that regulate stem cell maintenance.
Jiang et al used serially transplantable blast crisis progenitors in a mouse model and showed BCR-ABL amplification and enhanced expression of an IFN-responsive ADAR1 p150 isoform
The authors suggest that techniques directed against ADAR1 might be useful in eradication of CML LSC
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant CML
Imatinib, nilotinib and dasatinib all possess weak off-target activity against BRAF and CRAF in a RAS dependent manner. Because RAS is activated by BCR-ABL RAS activity may persist in the presence of TKIs. The authors have shown that nilotinib synergises with MEK inhibitors to kill drug resistant CML cells and block leukemia growth in mice
Packer et al, Cancer Cell 2011; 20: 715-727
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant CML
PD = PD184352
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant CML
Packer et al, Cancer Cell 2011; 20: 715-727
12-prostglandin J3 was identified by screening publically
acquired databases of cyclopentenone prostaglandins.The agent alleviates the development of leukemia in a murine model system – both in mice infected with a Friend erythro-leukemia virus and mice expressing a BCR-ABL oncogene in their haematopoietic compartment
12-prostglandin J3, an omega 3 fatty acid-derived metabolite, selectively ablates leukemia stem cell in mice
Hegde et al, Blood 2011;118: 6909
12-prostaglandin J3, an omega 3 fatty acid-derived metabolite, selectively ablates
leukemia stem cell in mice
Hegde et al, Blood 2011;118: 6909
A common polymorphism in the BIM gene contributes to intrinsic resistance to IM
Used massively parallel DNA sequencing of paired end ditags
Identified a novel deletion polymorphism in the BIM gene that is associated with deletion of exon 4 and the BH3 domain
12.3% of East Asian persons have this BIM deletion which is not seen in Africans or Caucasians
The BIM deletion inhibits imatinib-induced apoptosis in CML cells and so results in resistance to imatinib as well as to other TKIs
Ng, Tiong-Ong et al, Nat Med 2012;18: 521-528
Resistance to TKI results from deletion of exon 4 that contains BIMi2+/+ encoding BH3 transcripts that activate
apoptosis
Ng, Tiong-Ong et al, Nat Med 2012;18: 521-528
x
Ng, Tiong-Ong et al, Nat Med 2012;18: 521-528
Association of a BIM deletion polymorphism with clinical resistance to imatinib in CML-CP
AACR, Nature 2008; 454: 711
Chromosome
Transcription
Chromatin remodeller
Histones
Histone tails
Transcription
Non coding RNAs
Targeting epigenetic mechanisms in CML
Histone tail modifications DNA methylation
Chromatin remodeling
Non-coding RNAs
AACR, Nature 2008; 454: 711
Chromosome
Transcription
Chromatin remodeller
Histones
Histone tails
Transcription
Non coding RNAs
Targeting epigenetic mechanisms in CML
DNA methylation
Histone tail modifications Chromatin remodeling
Non-coding RNAs
Are there specific differences in the pattern of DNA methylation in CML and normal cells?
Does the pattern of methylation differ in different phases of CML?
Does the pattern of DNA methylation differ within chronic phase?
Does the pattern of DNA methylation differ in different sub-populations of Ph+ cells, eg CD34+ cells vs. GMP?
Questions that can now be addressed with epigenome wide studies to identify
aberrant DNA methylation
Are there specific differences in the pattern of DNA methylation in CML and normal
cells?
Bazeos et al. used Illumina 450 array based technology to study the methylation status CpG dinucleotides in DNA from CD34+ cells from 46 patients with CML-CP and normal controls
Results were compared with methylation patterns of 29 of the patients after they had achieved CCyR
DNA methylation analysis was clearly able to distinguish CML-CP, CML-CCyR and normal CD 34+ cells
Bazeos et al, poster presented at EHA-Amsterdam – June 2012
DIAGNOSIS NORMALS
CCyR
Unsupervised hierarchical clustering (Bazeos et al, 2013)
DNA methylation patterns in CMLH
eigh
t
Residual disease: % BCR-ABL/ABL mRNA % BCR-ABL DNA
28.22
1.82 2.08
0.030.060.04
0.09
UND UND
2.228
3 6 12 15 18
Months
0.054 0.016 0.009 0.006 0.0050.003 0.002
0.001
21 27 36 42
Low Level Positivity of g-PCR When RT-PCR Is Negative
Mattarucchi E, et al. J Mol Diagn. 2009;11:482-487.
Molecular monitoring of residual in CML – RT-PCR compared with genomic PCR
One approach to improving the efficacy of TKI should be to add a signal transduction inhibitor, but the ideal agent as not yet been identified
It should be possible to identify agents that act directly on the LSC, regardless of whether the LSC is quiescent or active and regardless of whether it is or is not oncogene addicted
Conclusions (1)
The fundamental heterogeneity of CML remains largely unexplained. It could be due in part to constutional factors or to epigenetic factors. The pattern of DNA methylation of CML cells differs substantially from that of their normal counterparts.
A DNA based PCR might be more informative than a RNA based PCR, especially when discontinuation of TKI is being considered.
Conclusions (2)
Imperial College Non-Imperial
Jane Apperley Michael Deininger
Mary Alikian Ong Tiong
David Marin Tessa Holyoake
Gareth Gerrard Tom O’Hare
Alex Bazeos Nick Cross
Thanks especially to